^
Association details:
| Biomarker: | FLT3 G619C |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Excerpt:
...samples from FLT3 ITD mutated AML patients who relapsed while on sorafenib. Indeed, in addition to the ITD mutations we identified acquired FLT3 point mutations in 2 of 4 patients, which were also located in the TKDs (i.e., G619C, D651G, and I687F)...
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-2052
